In today’s briefing:
- Akums Drugs and Pharmaceuticals: Limited Downside Is Seen, Long-Term Growth Story Intact
- Pre-IPO Herbs Generation Group Holdings (PHIP Updates) – Some Points Worth the Attention
- UnitedHealth in Crisis? CEO’s Tragic Death and Bipartisan Bill Shake Healthcare Giant!
- SanBio Co Ltd (4592 JP): Q3 FY01/25 flash update
- SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
- DNA Synthesis with a Silicon Twist
- LGND: 2025 View Calls for 17% Topline Growth
Akums Drugs and Pharmaceuticals: Limited Downside Is Seen, Long-Term Growth Story Intact
- Akums Drugs and Pharmaceuticals (0200361D IN) shares are currently trading below their IPO price post Q2FY25 result announcement. Compared with year-ago quarter, Q2FY25 revenue and adjusted EBITDA declined.
- Digging deeper into the seemingly weak Q2FY25 result, we have come across some positive takeaways. With some of the recent developments, the company is well-positioned for long-term growth.
- The share price reaction is overdone. Over the last one month, Akums shares gained 6.5% and outperformed most of its domestic peers, as the long-term growth prospect remains intact.
Pre-IPO Herbs Generation Group Holdings (PHIP Updates) – Some Points Worth the Attention
- Performance declined sharply in 24H1 mainly due to the decrease in orders from Customer A. Herbs Generation’s business/financial performance would be easily affected if the contributions from Customer A decline.
- Current sales model of Herbs Generation is hard to change, and the Company still has to invest heavily in offline marketing and promotional efforts, but the efficiency is not high.
- Herbs Generation’s ability to resist risks is relatively weak, which prevents us from building optimistic expectations for sustainable growth in the future. Valuation should be lower than peers.
UnitedHealth in Crisis? CEO’s Tragic Death and Bipartisan Bill Shake Healthcare Giant!
- UnitedHealth Group reported a strong financial performance in the third quarter of 2024, with revenues reaching $101 billion, marking a more than 9% increase over the prior year.
- This growth was driven by significant contributions from both the Optum and UnitedHealthcare divisions.
- Optum Health revenues grew by over $2 billion to approach $26 billion, and Optum Rx revenues increased by more than $5 billion to exceed $34 billion.
SanBio Co Ltd (4592 JP): Q3 FY01/25 flash update
- In cumulative Q3 FY01/25, SanBio reported no operating revenue, with an operating loss of JPY2.5bn, narrowing YoY.
- Non-operating income was JPY504mn, primarily from foreign-exchange gains; recurring loss was JPY2.0bn, increasing YoY.
- Net loss attributable to owners was JPY2.2bn; deferred tax liabilities and extraordinary gains impacted financial results.
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway
- On December 16, 2024, Soligenix, Inc. (SNGX) announced it has opened patient enrollment for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with cutaneous T cell lymphoma (CTCL).
- This trial is supported by the statistically significant results from the Phase 3 FLASH study along with a successful comparator study and an ongoing investigator-initiated study.
- The trial will enroll approximately 80 patients across the U.S. and E.U. Patients will be treated for 18 consecutive weeks before being assessed for the study’s primary endpoint.
DNA Synthesis with a Silicon Twist
- Twist Bioscience (TWST US) fosters a new biotech paradigm by empowering startups and researchers with scalable tools, accelerating innovation and transforming biotech into a more agile, tech-style founder-driven industry.
- DNA synthesis should see strong growth (15-25% CAGR estimates) driven by synthetic biology revolutionizing healthcare, agriculture, and industry with precise, scalable solutions for gene editing and bioengineering.
- Lack of profitability and notable short-seller interest are concerns, but its innovative platform, high innovation score and transformative potential makes a somewhat risky but very good investment case
LGND: 2025 View Calls for 17% Topline Growth
- Ligand Pharmaceuticals holds a portfolio of revenue, royalty & milestone generating assets that have been vetted by its internal investment team.
- Ligand considers individual biopharmaceutical products, platforms, companies & income streams in its opportunity set.
- It targets late-stage and commercial income-producing assets when making investments.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
